# NuvoAir Medical

> NuvoAir Medical is a virtual-first cardiopulmonary care company that helps patients with chronic heart and lung conditions - COPD, asthma, and CHF - manage their health from home before they end up in a hospital. Founded in Stockholm in 2015-2016 by Lorenzo Consoli and now headquartered in Boston, NuvoAir pairs FDA-cleared connected devices like the Air Next home spirometer with a clinical care team and data-driven monitoring. Its model is built around value-based care, with studies showing meaningful reductions in medical spend and hospitalizations. The company also powers decentralized clinical trials for pharma partners.

- **Founded:** 2015
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Lorenzo Consoli (Founder & CEO)
- **Team size:** ~71 employees
- **Products:** Air Next Spirometer, NuvoAir Home Service, Digital care platform, Clinical trials / decentralized trials platform
- **Notable:** Air Next spirometer received FDA 510(k) clearance for full in-home use (January 2024), PROMISE study interim report showed 27% reduction in medical spend versus matched controls, Nearly one-third fewer patients required inpatient care under the Home Service

## Products & services

- **Air Next Spirometer** — A Bluetooth-enabled, smartphone-connected handheld spirometer. FDA 510(k)-cleared in January 2024 for full in-home spirometry, allowing patients to run comprehensive lung function tests at home for conditions like COPD, asthma and ALS.
- **NuvoAir Home Service** — A virtual-first cardiopulmonary care program combining connected devices, remote monitoring and a clinical care team that supports patients with COPD, asthma and CHF between visits.
- **Digital care platform** — Software for remote patient monitoring, care coordination, risk stratification and automated reporting, integrating connected spirometers, inhaler sensors and wearables.
- **Clinical trials / decentralized trials platform** — A platform used by pharmaceutical companies and CROs to capture respiratory endpoints and run decentralized, remote clinical trials.

## Achievements

- Air Next spirometer received FDA 510(k) clearance for full in-home use (January 2024)
- PROMISE study interim report showed 27% reduction in medical spend versus matched controls
- Nearly one-third fewer patients required inpatient care under the Home Service
- Reported reducing urgent consultations by over 39%
- Raised a total of $28M, including a $25M Series A
- Reported 500% growth in Q1 2021

## Latest updates

- **2024-04** — Partnered with Privia Medical Group - Georgia to expand virtual-first cardiopulmonary care.
- **2024-01** — Air Next spirometer received FDA 510(k) clearance for full in-home spirometry.
- **2024-01** — Partnered with Cary Medical Management to reach patients in rural North Carolina.
- **2022-01** — Raised an $11M Series A extension led by Hikma Ventures, bringing the round to $25M.

## Links

- Website: https://nuvoair.com
- LinkedIn: https://www.linkedin.com/company/nuvoair
- Twitter/X: https://twitter.com/NuvoAir
- Facebook: https://www.facebook.com/NuvoAir/

---

Profile page: https://yespress.io/nuvoair-medical
Published by YesPress — https://yespress.io
Last updated: 2026-06-13